Every 10-Q that Dyadic Intl Inc Del (DYAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DYAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYAI filings page.
Dyadic International, Inc. reported second-quarter 2026 results showing a small revenue increase but continued significant losses and liquidity pressure. Total revenue for the six months ended June 30, 2026 was $2,072,094, up from $1,360,202 a year earlier, driven mainly by grant revenue and collaboration work. However, net loss for the six months was $4,078,567, only slightly higher than the prior-year loss of $3,821,353, as operating expenses remained well above revenue.
As of June 30, 2026, Dyadic held $4.8 million in cash, cash equivalents, restricted cash and investment securities and reported stockholders’ deficit of $2,387,244, compared with positive equity at year-end 2025. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing recurring losses, negative operating cash flow of $3,781,366 in the first half, and a long-term accumulated deficit of $97,529,675.
The company is rebranding as Dyadic Applied BioSolutions and shifting focus toward commercializing non-therapeutic protein products using its Dapibus™ and C1 platforms. It relies heavily on external funding, including a $3,092,136 Gates Foundation grant, up to $2,432,756 from a CEPI-related grant, $5.09 million of 8% Senior Secured Convertible Notes outstanding, and a $4,238,000 at-the-market equity program that had not been utilized by the report date.
Dyadic International, Inc. reported first-quarter 2026 revenue of $1.11 million, up from $393,572 a year earlier, driven by research collaborations, grant funding and license milestones, including recognition of $273,000 from its Proliant serum albumin agreement and continued Gates Foundation and CEPI grant activity.
The company posted a net loss of $1.95 million for the quarter, slightly improved from a $2.03 million loss in 2025, as higher revenue was offset by increased general and administrative expenses of $1.76 million. Cash, cash equivalents, restricted cash and investment securities totaled about $6.6 million as of March 31, 2026, and management believes this will fund operations for at least 12 months.
Stockholders’ equity turned negative at $(0.41) million, and Dyadic remains dependent on external funding, including $5.09 million of 8% senior secured convertible notes and a new at‑the‑market program of up to $4.24 million. Recent milestones—such as Proliant’s commercial launch of AlbuFree DX, Inzymes milestones, and new distribution and OEM agreements—support its strategic shift toward revenue-focused, non‑animal protein applications.
Dyadic International (DYAI) filed its Q3 2025 report, showing lower revenue and a wider loss as it shifts toward commercial applications of its Dapibus and C1 protein platforms. Total revenue was $1,164,617 for the quarter (vs. $1,957,500 a year ago), driven by grant revenue and research services. Net loss was $1,976,012 (vs. $203,460), or $0.06 per share, as operating expenses and grant-related costs rose.
Liquidity improved with financing and awards. On August 1, the company completed an underwritten offering of 6,052,000 shares at $0.95, generating $4.9 million in net proceeds. As of September 30, 2025, Dyadic reported cash, cash equivalents, restricted cash and investments totaling about $10.4 million, and stated these resources are expected to cover at least the next 12 months. The company continued execution under a $3.09 million Gates Foundation grant and a CEPI award under which Dyadic may receive up to $2.4 million as a subcontractor.
Convertible notes issued in March 2024 remain outstanding at 8% interest, with a $1.40 conversion price set by amendment; a related trust purchased $1.0 million of the notes in September. Shares outstanding were 36,187,798 as of November 11, 2025.
Dyadic International, Inc. reported results for the quarter ended June 30, 2025, showing revenue growth and a smaller operating loss versus the prior year. Total revenue was $966,630 for the quarter (versus $385,896 a year earlier) and $1,360,202 for the six months (versus $720,513). Net loss for the quarter was $(1,793,774) compared with $(2,045,223) a year ago; six-month net loss was $(3,821,353) versus $(4,054,819). Basic and diluted loss per share was $(0.06) for the quarter and $(0.13) for six months.
Balance sheet and liquidity highlights show cash and cash equivalents of $2,140,899 and restricted cash of $1,833,531 related to the Gates Foundation grant. Total assets were $8.14 million and total liabilities $8.67 million, producing stockholders' equity of $(529,701). Convertible notes net carrying amounts were $1,070,971 (related party) and $3,930,170 (third party). Post-period the company closed an offering on August 1, 2025 that generated net proceeds of approximately $5.3 million; management states existing funds plus the offering are expected to cover at least 12 months, subject to assumptions stated in the filing.